Xaira

-80%

est. 2Y upside i

HealthcareSeries D+

Xaira is reinventing drug R&D using artificial intelligence to rapidly prototype and test disease treatments.

Rank

#3594

Sector

Biotechnology / AI Drug Discovery

Est. Liquidity

~4Y

Data Quality

Data: Low

Xaira's $4B valuation on only $20M revenue implies a 198x multiple, far above comps (10-20x).

Last updated: July 19, 2026

Bull (15%)-19%

Vertex partnership validates platform, premium multiple 40x; revenue reaches $101M; dilution reduces upside to -19%.

Base (45%)-82%

Multiple compresses to 15x (in line with comps); revenue $101M; dilution and preference stack erode value.

Bear (40%)-100%

Multiple collapses to 5x; exit value < $1B preferred; common stock returns -100%.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Funding Intensity

25%

Total preferred stock overhang is $1B, representing 25% of current valuation. In a downside exit, common stock holders recover nothing.

Dilution Risk

high

Likely need additional funding within 2 years due to high burn rate; estimated 20% dilution.

Secondary Liquidity

none

No secondary market activity reported.

Other — 1 role

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Xaira's data — designed to show you've done your homework.

1
“How does X-Cell differentiate from Recursion's AI platform?”
2
“What is the revenue model? Licensing, milestones, or internal pipeline?”
3
“Given the $1B raise two years ago, when is the next funding round expected and what does it mean for equity dilution?”

Our model estimates -80% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.